Edgen Stock·Dec 12 2025, 00:10Back
AbbVie Oncology Unit Grows on New Drug Momentum
Edgen Stock·Dec 12 2025, 00:10
[1] IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma - BioSpace (https://www.biospace.com/press-releases/ideay ...)[2] Pfizer Builds Case for Tukysa as ‘New Standard Regimen’ in First-Line Metastatic Breast Cancer - BioSpace (https://www.biospace.com/drug-development/pfi ...)[3] Lilly's obesity triple pulls off 29% weight loss in trial - pharmaphorum (https://pharmaphorum.com/news/lillys-obesity- ...)
